How do i treat cml

Sign In. Skip Nav Destination Content Menu. Close Abstract. Diagnosis, staging, and risk classification. Initial treatment.

The patient with CCyR. When do we change therapy? A few monitoring pearls. Treatment discontinuation. Article Navigation. This Site. Google Scholar. Hagop Kantarjian Hagop Kantarjian. Blood 7 : — Article history Submitted:. Cite Icon Cite. Table 1 Staging of CML that we use in our practice. View Large. Adverse events. Figure 1.

View large Download PPT. Table 3 When do we consider failure to therapy in CML and indications of treatment change. View large. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.

Search ADS. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Gene expression changes associated with progression and response in chronic myeloid leukemia. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.

Clinical significance of complete cytogenetic response CCyR and major molecular response MMR achieved with different treatment modalities used as frontline therapy in chronic myeloid leukemia CML chronic phase CP [abstract].

Comparison of imatinib mg and mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: month minimum follow-up of the phase 3 randomised ENESTnd trial.

Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Potent, transient inhibition of BCR-ABL with dasatinib mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: month follow-up results. Subset analysis of response to treatment of chronic phase CML in a phase 1 study of ponatinib in refractory hematologic malignancies [abstract].

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI IRIS. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients: a follow-up analysis of the German CML Study IV [abstract].

Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression: an update of the TIDEL-II trial [abstract].

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? Safety and efficacy of bosutinib SKI in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Subcutaneous omacetaxine in chronic or accelerated chronic myeloid leukemia resistant to two or more tyrosine-kinase inhibitors including imatinib [abstract].

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib STIM trial.

Funding for Cancer Training. Building a Diverse Workforce. National Cancer Act 50th Anniversary Commemoration. Resources for News Media. Media Contacts. Cancer Reporting Fellowships. Advisory Board Meetings.

Social Media Events. Cancer Currents Blog. Contributing to Cancer Research. Strategic Planning. Principal Deputy Director's Page. Previous NCI Directors.

NCI Frederick. Advisory Boards and Review Groups. NCI Congressional Justification. Current Congress. Committees of Interest. Legislative Resources. Recent Public Laws. Search Search. Home Cancer Types Leukemia Patient. Adult ALL Treatment. Adult AML Treatment. CML Treatment. Hairy Cell Leukemia Treatment.

Childhood ALL Treatment. Childhood AML Treatment. Key Points Chronic myelogenous leukemia is a disease in which the bone marrow makes too many white blood cells. Leukemia may affect red blood cells, white blood cells, and platelets. Signs and symptoms of chronic myelogenous leukemia include weight loss and tiredness. Most people with CML have a gene mutation change called the Philadelphia chromosome.

Tests that examine the blood and bone marrow are used to diagnose chronic myelogenous leukemia. Certain factors affect prognosis chance of recovery and treatment options. Red blood cells that carry oxygen and other substances to all tissues of the body. Platelets that form blood clots to stop bleeding.

Granulocytes white blood cells that fight infection and disease. Feeling very tired. Weight loss for no known reason. Drenching night sweats. Pain or a feeling of fullness below the ribs on the left side. Physical exam and health history : An exam of the body to check general signs of health, including checking for signs of disease such as an enlarged spleen.

Complete blood count CBC with differential : A procedure in which a sample of blood is drawn and checked for the following: The number of red blood cells and platelets. The number and type of white blood cells. The amount of hemoglobin the protein that carries oxygen in the red blood cells. The portion of the blood sample made up of red blood cells. Cytogenetic analysis : A laboratory test in which the chromosomes of cells in a sample of blood or bone marrow are counted and checked for any changes, such as broken, missing, rearranged, or extra chromosomes.

Changes in certain chromosomes, such as the Philadelphia chromosome, may be a sign of cancer. Cytogenetic analysis is used to help diagnose cancer, plan treatment, or find out how well treatment is working. FISH fluorescence in situ hybridization : A laboratory test used to look at and count genes or chromosomes in cells and tissues. When these dyed pieces of DNA attach to certain genes or areas of chromosomes in the sample, they light up when viewed under a fluorescent microscope.

The FISH test is used to help diagnose cancer and help plan treatment. Reverse transcription—polymerase chain reaction test RT—PCR : A laboratory test in which the amount of a genetic substance called mRNA made by a specific gene is measured. An enzyme called reverse transcriptase is used to convert a specific piece of RNA into a matching piece of DNA, which can be amplified made in large numbers by another enzyme called DNA polymerase.

RT-PCR can be used to check the activation of certain genes that may indicate the presence of cancer cells. This test may be used to look for certain changes in a gene or chromosome, which may help diagnose cancer. The phase of CML. The amount of blasts in the blood or bone marrow. Key Points After chronic myelogenous leukemia has been diagnosed, tests are done to find out if the cancer has spread.

Chronic myelogenous leukemia has 3 phases. Chronic phase Accelerated phase Blastic phase Chronic myelogenous leukemia can relapse return after it has been treated. Key Points There are different types of treatment for patients with chronic myelogenous leukemia. Six types of standard treatment are used: Targeted therapy Chemotherapy Immunotherapy High-dose chemotherapy with stem cell transplant Donor lymphocyte infusion DLI Surgery New types of treatment are being tested in clinical trials.

Treatment for chronic myelogenous leukemia may cause side effects. Patients can enter clinical trials before, during, or after starting their cancer treatment. Follow-up tests may be needed. Tyrosine kinase inhibitor therapy : This treatment blocks the enzyme , tyrosine kinase, that causes stem cells to develop into more white blood cells blasts than the body needs.

Imatinib mesylate Gleevec , dasatinib , nilotinib , ponatinib , and bosutinib are tyrosine kinase inhibitors used to treat CML. Interferon : Interferon affects the division of cancer cells and can slow tumor growth. Treatment of chronic phase chronic myelogenous leukemia may include the following: Targeted therapy with a tyrosine kinase inhibitor imatinib mesylate , nilotinib , dasatinib , bosutinib. High-dose chemotherapy with donor stem cell transplant. A clinical trial of lower- dose chemotherapy with donor stem cell transplant.

In addition to the side effects mentioned above, side effects of chemotherapy injections can include:. The side effects should pass after your treatment has finished, although there's a risk that infertility could be permanent. A stem cell or bone marrow transplant is the only potential cure for CML, but it's a very intensive treatment and is not suitable for many people with the condition.

This is where donated cells called stem cells which produce white blood cells are transplanted into your body so you start to produce healthy white blood cells. The high doses of chemotherapy and radiotherapy can put an enormous strain on the body and can cause significant side effects and life-threatening complications. Transplants are generally only considered in younger people with CML, people in good general health and ideally those with a sibling who can provide a donation, as it's more likely to be successful in these cases.

But in many cases of CML, the potential risks of transplantation far outweigh the potential benefits, particularly now that treatment with imatinib can often keep the condition under control for many years.

In the UK, a number of clinical trials are under way that aim to find the best way to treat leukaemia. Clinical trials are studies that use new and experimental techniques to see how well they work in treating and possibly curing diseases. You should be aware there's no guarantee the techniques being studied in the clinical trial will be more effective than current treatments.

Your care team will be able to let you know whether there are any clinical trials available in your area, as well as explaining the benefits and risks involved. Page last reviewed: 18 September Next review due: 18 September Imatinib A medicine called imatinib is now the main treatment for CML. The side effects of imatinib are usually mild and should improve with time.

A bone marrow transplant is a medical procedure in which bone marrow that contains leukemia is replaced by highly specialized cells, called hematopoietic stem cells, that develop into healthy bone marrow. Hematopoietic stem cells are blood-forming cells found both in the bloodstream and in the bone marrow. Today, this procedure is more commonly called a stem cell transplant, rather than bone marrow transplant, because it is the stem cells in the blood that are typically being transplanted, not the actual bone marrow tissue.

Before recommending transplantation, doctors will talk with the patient about the risks of this treatment. Although a bone marrow transplant is the only treatment that can cure CML, it is used less often now.

This is because bone marrow transplants have a lot of side effects, while TKIs are very effective for CML and have fewer side effects.

Side effects depend on the type of transplant, your general health, and other factors. Learn more about the basics of stem cell and bone marrow transplantation.

Leukemia and its treatment often cause side effects. This approach is called palliative or supportive care, and it includes supporting the patient with his or her physical, emotional, and social needs. Palliative care is any treatment that focuses on reducing symptoms, improving quality of life, and supporting patients and their families.

Any person, regardless of age or type of cancer, may receive palliative care. It works best when palliative care is started as early as needed in the cancer treatment process. People often receive treatment for the leukemia at the same time that they receive treatment to ease side effects. In fact, people who receive both at the same time often have less severe symptoms, better quality of life, and report they are more satisfied with treatment.

Palliative treatments vary widely and often include medication, nutritional changes, relaxation techniques, emotional support, and other therapies. You may also receive palliative treatments similar to those meant to eliminate the leukemia, such as chemotherapy. Talk with your doctor about the goals of each treatment in your treatment plan. Before treatment begins, talk with your health care team about the possible side effects of the specific treatment plan and palliative care options.

During and after treatment, be sure to tell your doctor or another health care team member if you are experiencing a problem so it can be addressed as quickly as possible. Learn more about palliative care. The immediate goals of treatment are to reduce any symptoms of CML. The longer-term goals are to decrease or get rid of the cells with the Philadelphia chromosome to slow down or prevent the disease from moving to blast phase.

Treatment will often first include a TKI see Targeted therapy, above. Dasatinib or nilotinib are more effective in providing longer remissions, but many patients have the CML return within about 2 years. Therefore, an ALLO stem cell transplantation should be considered when possible. If an ALLO stem cell transplantation is not recommended or if a matched donor cannot be found, the treatment plan may include a different TKI or a clinical trial. If the transplant can be done while imatinib or dasatinib is working, then the long-term results are better.

Many people with CML in blast phase receive imatinib or dasatinib plus chemotherapy similar to that used for patients with acute leukemia, such as acute myeloid leukemia AML or acute lymphoblastic leukemia ALL.

Hydroxyurea see Chemotherapy, above is often given to patients because it can help control blood cell levels. If the leukemia does not respond to treatment, it is a good idea to talk with doctors who have experience in treating resistant CML.

Doctors can have different opinions about the best standard treatment plan. Clinical trials might also be an option. Learn more about getting a second opinion before starting treatment, so you are comfortable with your chosen treatment plan.

This discussion may include clinical trials. Palliative care will also be important to help prevent and relieve symptoms and side effects. For most people, a diagnosis of resistant leukemia can be very stressful. You and your family are encouraged to talk about how you feel with doctors, nurses, social workers, or other members of the health care team.

It may also be helpful to talk with other patients, including through a support group. It is not yet proven whether imatinib, dasatinib, or nilotinib, or the newer drugs bosutinib, ponatinib, or omacetaxine can cure CML. A remission is when leukemia cannot be detected in the body by cytogenetic testing and there are no symptoms. A remission may be temporary or permanent.

This uncertainty causes many people to worry that the leukemia will come back. While many remissions are permanent, it is important to talk with your doctor about the possibility of the disease returning. Understanding your risk of having the disease come back and the treatment options may help you feel more prepared if the leukemia does return.

Learn more about coping with the fear of the CML returning. If the leukemia does return despite the original treatment, a new cycle of testing will begin again to learn as much as possible about the disease. After this testing is done, you and your doctor will talk about the treatment options. Often the treatment plan will include the treatments described above such as targeted therapy, chemotherapy, and immunotherapy, but they may be used in a different combination or given at a different dose.

Your doctor may suggest clinical trials that are studying new ways to treat this type of leukemia. Whichever treatment plan you choose, palliative care will be important for relieving symptoms and side effects. People with leukemia that has come back after remission often experience emotions such as disbelief or fear. You are encouraged to talk with the health care team about these feelings and ask about support services to help you cope.

Learn more about dealing with CML that comes back. Recovery from leukemia is not always possible.